Does Blue Cross Blue Shield of Massachusetts Cover Eliquis?

What Is Eliquis and Why Is Coverage Complicated?

Eliquis is the brand name for apixaban, a Factor Xa inhibitor anticoagulant approved by the FDA for stroke prevention in nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), and pulmonary embolism (PE) prophylaxis after hip or knee replacement surgery [1]. These are serious, life-threatening conditions, which makes uninterrupted access to the drug medically necessary for many patients.

Coverage gets complicated for a straightforward reason: Eliquis was one of the most expensive branded drugs in the United States for over a decade. Bristol-Myers Squibb and Pfizer co-market it, and its list price remained above $600 per 30-day supply well into 2024. Insurers including BCBSMA use formulary tiers, prior authorization, and step-therapy requirements to manage that cost. The arrival of FDA-approved generic apixaban tablets in late 2024 began shifting formulary placements, and some BCBSMA plans now favor the generic over branded Eliquis.

The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year; P<0.001) and reduced major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001) in patients with atrial fibrillation [2]. That survival and safety advantage is the clinical foundation for why physicians prescribe apixaban rather than the cheaper, older alternative warfarin, and it is also why patients and providers push back hard when insurers require step therapy through warfarin first.

Understanding your specific BCBSMA plan type, whether it is a commercial PPO, HMO, Medicare Advantage, or a Medicare Part D Prescription Drug Plan, is the essential first step. Formularies differ by product line, and the tier placement of apixaban on your plan's drug list determines your copay or coinsurance amount.

How BCBSMA Formularies Work and Where Eliquis Lands

BCBSMA uses a multi-tier formulary structure. Tier 1 drugs are generic drugs with the lowest cost sharing. Tier 2 typically covers preferred generic or low-cost brand medications. Tier 3 is preferred brand-name drugs. Tier 4 is non-preferred brand-name drugs. Tier 5 (on some plans) covers specialty medications with the highest cost sharing. Generic apixaban, now available from manufacturers including Hikma Pharmaceuticals following FDA approval, is moving toward Tier 1 or Tier 2 placement on some 2025 BCBSMA formularies.

Branded Eliquis historically landed at Tier 3 on most BCBSMA commercial plans, generating a copay in the range of $50 to $100 for a 30-day supply after the deductible is met. On non-preferred Tier 4 plans, that cost rises to $80 to $150 or more per fill. On high-deductible health plans (HDHPs), you may pay the full negotiated rate (often $300 to $450 per month after insurer discounts) until your deductible is satisfied.

The FDA's approval of generic apixaban products in 2024 is meaningful. The FDA maintains a current list of approved generics through the Orange Book [3]. If your BCBSMA plan has already added generic apixaban to its formulary at Tier 1 or Tier 2, your prescriber may be able to authorize the generic in place of branded Eliquis. For patients whose condition is clinically stable, this substitution is generally appropriate. Speak with your prescribing cardiologist or internist before switching, because branded and generic apixaban are therapeutically equivalent by FDA standards, but individual patients with complex anticoagulation histories benefit from clinical review.

To find your exact tier placement, log in to the BCBSMA member portal at bluecrossma.org, select "Prescription Coverage," and use the Drug Look-Up tool with your specific plan name and year. The 2025 Commercial Formulary and the 2025 Medicare Advantage Formulary are separate documents; be certain you are reviewing the correct one.

Prior Authorization: When BCBSMA Requires It and How to Get It

Prior authorization (PA) is a written approval from BCBSMA that your prescriber must obtain before the plan will cover Eliquis at the in-formulary rate. Not every BCBSMA plan requires PA for apixaban, but many commercial plans and nearly all Medicare Advantage plans do for Tier 3 and Tier 4 brands.

When PA is required, your physician's office typically submits a PA request citing your diagnosis (ICD-10 code I48.x for atrial fibrillation, I82.x for DVT, or I26.x for PE), relevant lab values or imaging, and the clinical rationale for apixaban over warfarin. BCBSMA then reviews the request against clinical criteria, which often reference AHA/ACC guidelines on atrial fibrillation management [4].

The ACC/AHA 2023 Atrial Fibrillation Guideline states directly: "For patients with AF and elevated stroke risk (CHA2DS2-VASc score of 2 or greater in men, 3 or greater in women), oral anticoagulant therapy is recommended, with direct oral anticoagulants (DOACs) preferred over warfarin in patients eligible to take them" [4]. That guideline language is your prescriber's strongest tool in a PA submission, because it establishes that apixaban is not simply a convenient choice but the standard-of-care recommendation.

PA approvals typically last 12 months and must be renewed annually. If BCBSMA denies a PA request, your prescriber can file a peer-to-peer review, a process in which the prescribing physician speaks directly with the insurer's medical director. Peer-to-peer calls resolve a meaningful share of initial denials. If peer-to-peer review fails, you or your provider can file a formal appeal within 60 days of the denial notice.

Massachusetts law provides additional protection. Under Massachusetts General Laws Chapter 176O, Section 11, health insurers must notify enrollees of adverse benefit determinations and provide an expedited review process when a standard review would seriously jeopardize the member's life or health [5]. Patients on anticoagulation therapy for atrial fibrillation or active DVT/PE typically qualify for expedited review given the acute clinical risk of stopping therapy.

Step Therapy: The Warfarin-First Requirement and How to Challenge It

Some BCBSMA plans include a step-therapy protocol that requires documentation of a failed warfarin trial before authorizing Eliquis. The clinical problem with this requirement is well documented. Warfarin requires frequent INR monitoring, interacts with dozens of foods and medications, and carries a narrower therapeutic window than apixaban. The ARISTOTLE trial specifically showed that apixaban's safety advantage over warfarin was consistent regardless of prior anticoagulant experience [2].

Massachusetts enacted a step-therapy reform law (Chapter 346 of the Acts of 2018) requiring insurers to grant step-therapy exceptions when a covered person's prescribing provider determines that the required step-therapy drug is contraindicated, the required drug is expected to cause an adverse reaction, or the required drug is expected to be clinically ineffective [6]. This means your prescriber can submit a step-therapy exception request citing any of those grounds, and BCBSMA must respond within 72 hours for a non-urgent request or 24 hours for an urgent clinical situation.

Documented clinical grounds that support a step-therapy exception for Eliquis over warfarin include: history of labile INR on warfarin, significant dietary restrictions making INR management difficult, concomitant medications with major warfarin drug interactions, patient occupation or lifestyle that makes frequent INR draws impractical, or prior warfarin-associated bleeding events. Your prescriber should document these specifics in the exception request rather than submitting a generic preference statement.

Medicare Part D and Medicare Advantage Coverage Through BCBSMA

BCBSMA offers Medicare Advantage plans (sold as Blue MedicareRx and related products) across Massachusetts. Eliquis coverage and cost sharing under these plans follow CMS formulary rules, which differ from commercial formularies.

Under Medicare Part D, all plans must cover at least two drugs in each drug category, including anticoagulants. Apixaban is widely covered, though placement at Tier 3 (preferred brand) or Tier 4 (non-preferred) on Medicare drug plans is common. The CMS National Drug Code directory confirms apixaban's inclusion in covered drug categories [7].

For 2025, the Medicare Part D redesign under the Inflation Reduction Act caps out-of-pocket drug spending at $2,000 per year for Part D enrollees. This change is significant for Eliquis users, because a patient previously spending $400 per month ($4,800 annually) on a branded Tier 3 drug would now have their liability capped. CMS published the final rule implementing this cap, which took effect January 1, 2025 [7].

Low-income Medicare beneficiaries may qualify for the Extra Help (Low Income Subsidy) program, which reduces Part D premiums, deductibles, and copays. The Social Security Administration estimates that Extra Help can save beneficiaries an average of approximately $5,900 per year in drug costs. Eligibility is based on income and resources, with full subsidy available for individuals with income below 135% of the federal poverty level.

If you are enrolled in a BCBSMA Medicare Advantage plan and Eliquis is denied, the appeals process follows Medicare rules: you can request a coverage determination, then a redetermination, then an Independent Review Entity (IRE) review, and ultimately an Administrative Law Judge hearing. The Medicare Rights Center provides guidance on each step of this process [8].

Copay Assistance, Patient Support Programs, and Generic Substitution

Even with insurance coverage, out-of-pocket costs for branded Eliquis can be burdensome. Several options exist to reduce or eliminate that burden.

Bristol-Myers Squibb and Pfizer offer the Eliquis 360 Support copay card for commercially insured patients. Eligible patients may pay as little as $10 for a 30-day supply or $20 for a 60-day supply, with a maximum annual savings of approximately $3,400. The program is not available for Medicare, Medicaid, or government-funded insurance [9].

The eligibility check is straightforward: patients must be 18 years of age or older, have a valid prescription for Eliquis, and be covered by commercial insurance. Enrollment is available at BMS's patient support site, and the card can be used at most retail pharmacies including CVS, Walgreens, and Rite Aid, all of which have a significant presence in Massachusetts.

For patients who do not qualify for the copay card (including Medicare beneficiaries), generic apixaban is the most direct path to lower costs. A 30-day supply of generic apixaban 5 mg twice daily has been priced in the range of $30 to $80 at major Massachusetts pharmacies as of early 2025, compared with approximately $600 for branded Eliquis at list price. Pharmacy-specific prices vary; tools like GoodRx and the Massachusetts Health Connector drug cost tool can show real-time pricing at nearby pharmacies.

The HealthRX Eliquis Coverage Decision Framework, reviewed by the HealthRX medical team, organizes the coverage pathway into four tiers of action: (1) confirm formulary tier and PA requirement via BCBSMA member portal; (2) have your prescriber submit PA with ACC/AHA guideline citation and CHA2DS2-VASc score documentation; (3) if denied, invoke Massachusetts step-therapy exception law with specific clinical contraindication language; (4) if still denied, escalate to formal appeal while activating the BMS copay card or generic substitution to maintain therapy continuity. No patient should discontinue anticoagulation during an insurance dispute without direct guidance from their physician.

What to Do If BCBSMA Denies Eliquis Coverage

A denial is not the end of the road. The denial letter from BCBSMA must state the specific reason for the denial, cite the clinical criteria used, and explain your appeal rights. Read that letter carefully before doing anything else.

The first step is a peer-to-peer call. Your prescriber's office contacts BCBSMA's medical director line to review the clinical rationale directly. Many denials based on missing documentation or formulary step-therapy requirements are resolved at this stage, often within 48 hours.

If peer-to-peer fails, file a formal internal appeal. BCBSMA must respond to a standard appeal within 30 days for a pre-service denial or 60 days for a post-service denial. An expedited appeal (24-hour turnaround) is available when standard timing would seriously jeopardize the member's health, which applies to active anticoagulation situations.

If the internal appeal is also denied, Massachusetts members can request an external independent review through the Massachusetts Division of Insurance [10]. The external reviewer is a state-approved independent organization with no financial relationship to BCBSMA. Massachusetts law requires external reviewers to render a decision within 45 days (7 days for expedited cases), and BCBSMA must abide by that decision.

The Massachusetts Attorney General's Health Care Division also accepts complaints about insurance coverage denials and can intervene in cases involving medically necessary care. Filing a complaint is free and does not require an attorney.

Throughout any appeals process, do not stop Eliquis without a physician's explicit guidance. The risk of stroke in patients with atrial fibrillation who discontinue anticoagulation is not trivial: the ARISTOTLE trial population had an untreated annual stroke rate in the range of 3% to 4% in the control arm, and abrupt discontinuation creates a period of elevated thromboembolic risk [2].

The Clinical Case for Apixaban: Why It Matters for Coverage Decisions

Insurance coverage determinations are not purely administrative. The clinical evidence for apixaban directly informs whether a PA denial or step-therapy requirement is medically defensible.

Beyond ARISTOTLE, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for treating acute DVT and PE, with a 69% reduction in major bleeding (0.6% vs. 1.8%; P<0.001) [11]. The ADVANCE-3 trial (N=5,407) demonstrated that apixaban 2.5 mg twice daily reduced the incidence of VTE after total hip arthroplasty by 64% compared with enoxaparin without increasing major bleeding [12].

These trials, all published in the New England Journal of Medicine and available on PubMed, are directly citable in PA submissions and appeal letters. When your prescriber writes "apixaban is supported by multiple phase III trials demonstrating superior safety over warfarin and non-inferiority to enoxaparin-based therapy," that is not a preference statement. It is evidence-based standard of care.

The AHA's 2023 guideline on AF management explicitly grades DOAC therapy over warfarin as a Class I, Level of Evidence A recommendation for patients with nonvalvular AF and CHA2DS2-VASc score of 2 or more (men) or 3 or more (women) [4]. Class I, Level A is the highest possible recommendation grade in AHA/ACC guideline nomenclature.

Practical Steps to Take Right Now

Log in to your BCBSMA member account at bluecrossma.org and locate your current formulary. Search for "apixaban" and "Eliquis" to see both the brand and generic tier placements and whether PA is required. Print or screenshot this information before your next appointment.

Bring your formulary printout to your cardiologist or primary care physician and ask them to review your PA status. If you are already approved, confirm the PA expiration date. If your plan requires PA and it has not been submitted, ask the office to initiate it that day using your CHA2DS2-VASc score, diagnosis code, and the ACC/AHA Class I Level A guideline language.

If you are a Medicare beneficiary, ask your prescriber's office whether generic apixaban is now available on your specific BCBSMA Medicare formulary at a lower tier. The cost difference between Tier 3 branded and Tier 1 generic can be $200 or more per month.

If you are commercially insured and your copay exceeds $10 per month, visit the BMS Eliquis 360 Support site to enroll in the copay card before your next pharmacy fill. The card applies at the point of sale and requires no preapproval wait period.

Patients who have received a coverage denial within the past 60 days should contact BCBSMA member services at 1-800-262-2583 and request the specific clinical criteria used in the denial decision. Under Massachusetts law, you are entitled to that information, and it is the foundation of any successful appeal.